Subscribe To
VPHIF / 7 Penny Stocks to Buy as a New Bull Market Emerges
VPHIF News
By Proactive Investors
October 5, 2023
Valeo Pharma CEO credits Enerzair for strong position on Canada's top-growing companies list
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) CEO Steve Saviuk joined Proactive's Stephen Gunnion to discuss the company's strong position on the Globe an more_horizontal
By Proactive Investors
October 4, 2023
Valeo Pharma secures spot on Canada's top-growing companies list
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) highlighted to investors that it has placed at spot 151 on the Globe and Mail's Report on Business annual lis more_horizontal
By Proactive Investors
September 14, 2023
Valeo Pharma reports record quarterly revenue or strong demand for Enerzair and Atectura therapies
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported its seventh consecutive rise in revenues to a quarterly record due to strong growth in its Enerz more_horizontal
By Proactive Investors
September 1, 2023
Valeo Pharma raises funds totalling $4.5M
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has closed a non-brokered private placement offering, raising gross proceeds of $3.92 million. The company a more_horizontal
By Proactive Investors
June 22, 2023
Valeo Pharma bolsters board with two new directors
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said Tamara Close and Didier Leconte have both joined its board of directors, noting that following the appo more_horizontal
By Proactive Investors
June 14, 2023
Valeo Pharma reports record quarterly revenues
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported record quarterly revenues of $13.6 million for its second quarter ending April 30, 2023, repr more_horizontal
By Proactive Investors
May 25, 2023
Valeo Pharma expects 2Q revenues to set quarterly record
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said it expects revenues in the second quarter to exceed $13.5 million, a quarterly record, with operating ex more_horizontal
By Proactive Investors
March 16, 2023
Valeo Pharma reports record 1Q revenue and gross profit buoyed by new products and higher market share
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said its revenue for the first quarter ended January 31, 2023, rose by 210% to a record $13.2 million, up fro more_horizontal